These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37024851)

  • 21. Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study.
    Ogawa H; Isshiki T; Kimura T; Yokoi H; Nanto S; Takayama M; Kitagawa K; Nishikawa M; Miyazaki S; Ikeda Y; Nakamura M; Tanaka Y; Saito S
    J Cardiol; 2016 Jul; 68(1):29-36. PubMed ID: 26521100
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Correlation between CYP2C19 Gene Polymorphism and Elderly Cerebral Infarction].
    Fan DJ; Li CY; Chen J; Ye ZQ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2018 Dec; 40(6):765-768. PubMed ID: 30606386
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The pharmacokinetic and pharmacodynamic interaction of clopidogrel and cilostazol in relation to CYP2C19 and CYP3A5 genotypes.
    Kim HS; Lim Y; Oh M; Ghim JL; Kim EY; Kim DH; Shin JG
    Br J Clin Pharmacol; 2016 Feb; 81(2):301-12. PubMed ID: 26426352
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Analysis of the association of CYP450 gene polymorphisms with ischemic stroke].
    Qi L; Liu Y; Qi M; Peng Y; Sun G; Yue Y
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2023 Apr; 40(4):500-504. PubMed ID: 36972950
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of CYP2C19 genetic polymorphisms on the cure rates of
    Zhao X; Zhang Z; Lu F; Xiong M; Jiang L; Tang K; Fu M; Wu Y; He B
    Front Pharmacol; 2022; 13():938419. PubMed ID: 36278195
    [No Abstract]   [Full Text] [Related]  

  • 26. Influence of CYP2C19 Polymorphisms on the Pharmacokinetics of Omeprazole in Elderly Subjects.
    Na JY; Jeon I; Yoon J; Choi Y; Yoon SH; Yu KS; Chung JY
    Clin Pharmacol Drug Dev; 2021 Dec; 10(12):1469-1477. PubMed ID: 34337876
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of CYP2C19 Gene Polymorphisms on Proton Pump Inhibitor, Amoxicillin, and Levofloxacin Triple Therapy for Eradication of Helicobacter Pylori.
    Lin YA; Wang H; Gu ZJ; Wang WJ; Zeng XY; Du YL; Ying SS; Zhang BH
    Med Sci Monit; 2017 Jun; 23():2701-2707. PubMed ID: 28577017
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association between genetic polymorphisms of cytochrome P450 2C19 and the risk of cerebral ischemic stroke in Chinese.
    Gu S; Sun Y; Han R; Wang L; Wang D; Wang J; Li X
    BMC Med Genet; 2014 Jul; 15():83. PubMed ID: 25030528
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure: A Systematic Review and Meta-analysis.
    Milosavljevic F; Bukvic N; Pavlovic Z; Miljevic C; Pešic V; Molden E; Ingelman-Sundberg M; Leucht S; Jukic MM
    JAMA Psychiatry; 2021 Mar; 78(3):270-280. PubMed ID: 33237321
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of CYP2C19*2 and *3 genetic variants with essential hypertension in Koreans.
    Shin DJ; Kwon J; Park AR; Bae Y; Shin ES; Park S; Jang Y
    Yonsei Med J; 2012 Nov; 53(6):1113-9. PubMed ID: 23074110
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of CYP2C19 polymorphism and proton pump inhibitors on platelet reactivity to clopidogrel and clinical outcomes following stent implantation.
    Hokimoto S; Mizobe M; Akasaka T; Arima Y; Kaikita K; Nakagawa K; Ogawa H
    Thromb Res; 2014 Apr; 133(4):599-605. PubMed ID: 24440142
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of esomeprazole on platelet reactivity and clinical outcome according to CYP2C19 genotype in coronary heart disease patients during dual antiplatelet therapy.
    Hokimoto S; Akasaka T; Tabata N; Arima Y; Tsujita K; Sakamoto K; Kaikita K; Morita K; Kumagae N; Yamamoto E; Oniki K; Nakagawa K; Ogawa H
    Thromb Res; 2015 Jun; 135(6):1081-6. PubMed ID: 25891840
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Association between genetic polymorphisms of CYP2C19 and CYP2C9 and phenytoin serum concentration].
    Huang Y; Yang JF; Qi XL; Wang YQ; Wang WZ; Chen B
    Zhonghua Yi Xue Za Zhi; 2004 Oct; 84(20):1686-9. PubMed ID: 15569425
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Prospective Study on the Usefulness of Initial Voriconazole Dose Adjustment Based on CYP2C19 Gene Polymorphism Analysis.
    Tanaka R; Fujioka T; Suzuki Y; Iwao M; Itoh H
    Chemotherapy; 2020; 65(3-4):59-64. PubMed ID: 32877905
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of cytochrome P450 2C19 polymorphisms on the Helicobacter pylori eradication rate following two-week triple therapy with pantoprazole or rabeprazole.
    Ormeci A; Emrence Z; Baran B; Gokturk S; Soyer OM; Evirgen S; Akyuz F; Karaca C; Besisik F; Kaymakoglu S; Ustek D; Demir K
    Eur Rev Med Pharmacol Sci; 2016 Mar; 20(5):879-85. PubMed ID: 27010145
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Platelet reactivity in the early and late phases of acute coronary syndromes according to cytochrome P450 2C19 phenotypes.
    Nagashima Z; Tsukahara K; Morita S; Endo T; Sugano T; Hibi K; Himeno H; Fukui K; Umemura S; Kimura K
    J Cardiol; 2013 Sep; 62(3):158-64. PubMed ID: 23886632
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: Meta-analysis of data from genome-wide association studies.
    Fabbri C; Tansey KE; Perlis RH; Hauser J; Henigsberg N; Maier W; Mors O; Placentino A; Rietschel M; Souery D; Breen G; Curtis C; Lee SH; Newhouse S; Patel H; O'Donovan M; Lewis G; Jenkins G; Weinshilboum RM; Farmer A; Aitchison KJ; Craig I; McGuffin P; Schruers K; Biernacka JM; Uher R; Lewis CM
    Eur Neuropsychopharmacol; 2018 Aug; 28(8):945-954. PubMed ID: 30135031
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
    Lee CR; Thomas CD; Beitelshees AL; Tuteja S; Empey PE; Lee JC; Limdi NA; Duarte JD; Skaar TC; Chen Y; Cook KJ; Coons JC; Dillon C; Franchi F; Giri J; Gong Y; Kreutz RP; McDonough CW; Stevenson JM; Weck KE; Angiolillo DJ; Johnson JA; Stouffer GA; Cavallari LH;
    Clin Pharmacol Ther; 2021 Mar; 109(3):705-715. PubMed ID: 32897581
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of CYP2C19 genotype on the time course of platelet aggregation inhibition after clopidogrel administration.
    Kim HS; Cho DY; Park BM; Bae SK; Yoon YJ; Oh M; Ghim JL; Kim EY; Kim DH; Shin JG
    J Clin Pharmacol; 2014 Aug; 54(8):850-7. PubMed ID: 24214141
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of CYP2C19 loss-of-function variants on the metabolism of clopidogrel in patients from north-western China.
    Lin R; Zhang L; Zhang P; Zhou L; Liu T; Li Y; Zhang W; Wang W; Zhang J
    J Clin Pharm Ther; 2015 Jun; 40(3):308-14. PubMed ID: 25810245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.